Literature DB >> 3752966

Type 2 and type 3 Gaucher disease: a morphological and biochemical study.

E M Kaye, M D Ullman, E R Wilson, J A Barranger.   

Abstract

Glucocerebroside levels were measured in the brains of patients with neuronopathic forms (types 2 and 3) of Gaucher disease and compared to those obtained from control brain. Nine separate brain regions (frontal, temporal, occipital, and cerebellar cortices; thalamus; corpus striatum; pons; medulla; and dentate nuclei) were analyzed. In all the Gaucher brains studied, the greatest glucocerebroside accumulation occurred within the occipital cortex, with lesser amounts in the temporal and frontal areas. The cerebellar cortex, corpus striatum, and thalamus in Gaucher brains had mildly increased levels of glucocerebroside, especially when the values were expressed as a percentage of total non-hydroxy fatty-acid cerebroside. Brainstem structures (pons and medulla) and dentate nuclei did not have increased glucocerebroside levels when compared to levels from similar control areas. However, when glucocerebroside concentration was expressed as a percentage of total non-hydroxy fatty-acid cerebroside, the type 2 Gaucher brainstem structures did show a slight increase in glucocerebroside levels over control levels. Neuropathological studies demonstrated the presence of Gaucher cells, gliosis, and microglial nodules within the type 2 brains. The neuropathological findings correlated with the glucocerebroside accumulation in the type 2 brains. Despite the similar pattern of glucocerebroside accumulation in the type 3 brain, no neuropathological abnormalities were seen. Thus, this study demonstrated that within several brain regions, both neuronopathic forms of Gaucher disease have elevated glucocerebroside levels, and that in the type 2 brains, the glucocerebroside accumulation correlated positively with the neuropathological findings.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752966     DOI: 10.1002/ana.410200208

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  27 in total

Review 1.  Gene transfer approaches to the lysosomal storage disorders.

Authors:  J A Barranger; E O Rice; W P Swaney
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 2.  The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.

Authors:  John DePaolo; Ozlem Goker-Alpan; Ted Samaddar; Grisel Lopez; Ellen Sidransky
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

Review 3.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 4.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

5.  Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III.

Authors:  Ahmed Abdel Khalek Abdel Razek; Nahed Abd El-Gaber; Ahmed Abdalla; Abeer Fathy; Ahmed Azab; Ashraf Abdel Rahman
Journal:  Neuroradiology       Date:  2009-07-15       Impact factor: 2.804

6.  Murine models of acute neuronopathic Gaucher disease.

Authors:  Ida Berglin Enquist; Christophe Lo Bianco; Andreas Ooka; Eva Nilsson; Jan-Eric Månsson; Mats Ehinger; Johan Richter; Roscoe O Brady; Deniz Kirik; Stefan Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

7.  Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.

Authors:  Benjamin Liou; Yanyan Peng; Ronghua Li; Venette Inskeep; Wujuan Zhang; Brian Quinn; Nupur Dasgupta; Rachel Blackwood; Kenneth D R Setchell; Sheila Fleming; Gregory A Grabowski; John Marshall; Ying Sun
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 8.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

9.  Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: a possible role in the neuronal loss.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Hum Genet       Date:  2004-06-04       Impact factor: 3.172

10.  Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.

Authors:  Ying Sun; Benjamin Liou; Huimin Ran; Matthew R Skelton; Michael T Williams; Charles V Vorhees; Kazuyuki Kitatani; Yusuf A Hannun; David P Witte; You-Hai Xu; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2010-01-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.